Myovant Sciences (MYOV)

Myovant Sciences Stock Analysis & Ratings

MYOV Stock Chart & Stats

Day’s Range$8.66 - $9.36
52-Week Range$7.67 - $27.43
Previous Close$8.61
Average Volume (3M)835.81K
Market Cap$878.96M
P/E Ratio-3.7
Next EarningsAug 09, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score3
EPS (TTM)-2.48



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Myovant Sciences’s price range in the past 12 months?
Myovant Sciences lowest stock price was $7.67 and its highest was $27.43 in the past 12 months.
    What is Myovant Sciences’s market cap?
    Myovant Sciences’s market cap is $878.96M.
      What is Myovant Sciences’s price target?
      The average price target for Myovant Sciences is $14.33. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $20.00 ,the lowest forecast is $11.00. The average price target represents 55.42% Increase from the current price of $9.22.
        What do analysts say about Myovant Sciences?
        Myovant Sciences’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 3 Wall Streets Analysts.
          When is Myovant Sciences’s upcoming earnings report date?
          Myovant Sciences’s upcoming earnings report date is Aug 09, 2022 which is in 85 days.
            How were Myovant Sciences’s earnings last quarter?
            Myovant Sciences released its earnings results on May 10, 2022. The company reported -$0.63 earnings per share for the quarter, missing the consensus estimate of -$0.544 by -$0.086.
              Is Myovant Sciences overvalued?
              According to Wall Street analysts Myovant Sciences’s price is currently Undervalued.
                Does Myovant Sciences pay dividends?
                Myovant Sciences does not currently pay dividends.
                What is Myovant Sciences’s EPS estimate?
                Myovant Sciences’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Myovant Sciences have?
                Myovant Sciences has 95,330,000 shares outstanding.
                  What happened to Myovant Sciences’s price movement after its last earnings report?
                  Myovant Sciences reported an EPS of -$0.63 in its last earnings report, missing expectations of -$0.544. Following the earnings report the stock price went up 24.036%.
                    Which hedge fund is a major shareholder of Myovant Sciences?
                    Among the largest hedge funds holding Myovant Sciences’s share is Platinum Investment Management. It holds Myovant Sciences’s shares valued at 3M.


                      Myovant Sciences Stock Analysis

                      Smart Score
                      Price Target
                      ▲(55.42% Upside)
                      Moderate Buy
                      The Myovant Sciences stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Myovant Sciences

                      Myovant Sciences, Inc. is a clinical-stage biopharmaceutical company. It focuses on developing and commercializing therapies for the treatment of women's health and endocrine diseases. The company's product includes relugolix, which is an oral, once-daily and small molecule that acts as a GnRH receptor antagonist. It also develops MVT-602 a kisspeptin agonist for the treatment of female infertility. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.

                      Similar Stocks
                      Price & Change
                      ObsEva SA
                      Palatin Technologies

                      Popular Stocks

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis